Phase I trial of Ipatasertib plus Atezolizumab enhances PI3K/AKT pathway immune responses in solid tumors and refractory glioblastoma
Loading...
Embargo End Date
Authors
Lopez, J
Tiu, C
Yau, W
Waldron, N
Ameratunga, M
Biondo, A
Zachariou, A
Crespo, M
Ferreira, A
Riisnaes, R
Gurel, B
Figueiredo, I
Bogdan, D
Yuan, W
Morilla, R
Swales, K
Decordova, S
Prout, T
Parmar, M
Baikady, B
Rata, M
Blackledge, M
Tunariu, N
Daly, R
Hu, X
Yap, C
Paschalis, A
Sharp, A
Banerji, U
Minchom, A
De Bono, J
Tiu, C
Yau, W
Waldron, N
Ameratunga, M
Biondo, A
Zachariou, A
Crespo, M
Ferreira, A
Riisnaes, R
Gurel, B
Figueiredo, I
Bogdan, D
Yuan, W
Morilla, R
Swales, K
Decordova, S
Prout, T
Parmar, M
Baikady, B
Rata, M
Blackledge, M
Tunariu, N
Daly, R
Hu, X
Yap, C
Paschalis, A
Sharp, A
Banerji, U
Minchom, A
De Bono, J
Document Type
Journal Article
Date
Date Accepted
2026-04-23
Abstract
Citation
Clinical Cancer Research,
DOI
Source Title
Clinical Cancer Research
Publisher
American Association for Cancer Research
ISSN
1078-0432
eISSN
1557-3265
Collections
Research Team
Adult DDU ICR & RM